PATENT CLAIM ANALYSIS

Application Number: 15743092
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2019-03
Patent Classification: ["435", "006130"]

Abstract:
A pharmaceutical composition containing a lung cancer therapeutic agent and an SIRT inhibitor may minimize the expression of the resistance of lung cancer cells against the lung cancer therapeutic agent, thereby exerting an excellent lung cancer therapeutic effect. The treatment of lung cancer cells with a lung cancer therapeutic agent and the measurement of a level of SIRT1 expression may provide information for determining whether lung cancer cells have developed chemoresistance to a lung cancer therapeutic agent, and may screen lung cancer therapeutic agents.

Claim (Index 2):
The pharmaceutical composition of  claim 1 , wherein the lung cancer therapeutic agent is one or more selected from the group consisting of cisplatin, carboplatin, oxaliplatin, and gemcitabine.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 86.0
- Lexical Diversity: 2.0
- Patent Class: 435.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['12026554', '12901139', '13058113', '14498618', '10508932']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6193918322473332
- 35 USC 102 Novelty (BERT): 0.5036078585496473
- Combined Prediction Score: 0.6078134348775646
- Mean Citation Score: 252.042706
- Max Citation Score: 261.61456
- Similarity Product: 176.8719476879406

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test